HC Wainwright Analysts Lower Earnings Estimates for Alumis

Alumis Inc. (NASDAQ:ALMS) – Equities researchers at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for Alumis in a note issued to investors on Thursday, March 20th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($1.29) per share for the quarter, down from their previous estimate of ($0.99). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis’ Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.01) EPS, Q4 2025 earnings at ($1.01) EPS and FY2025 earnings at ($4.26) EPS.

A number of other research firms have also recently commented on ALMS. Oppenheimer began coverage on shares of Alumis in a research note on Thursday, January 30th. They set an “outperform” rating and a $32.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Alumis presently has an average rating of “Buy” and a consensus price target of $26.00.

Alumis Stock Up 5.8 %

NASDAQ ALMS opened at $4.00 on Monday. Alumis has a 52 week low of $3.18 and a 52 week high of $13.53. The stock’s 50-day moving average price is $5.55 and its 200-day moving average price is $8.43.

Hedge Funds Weigh In On Alumis

Several institutional investors have recently bought and sold shares of ALMS. Tang Capital Management LLC boosted its holdings in shares of Alumis by 40.6% during the 4th quarter. Tang Capital Management LLC now owns 600,000 shares of the company’s stock valued at $4,716,000 after purchasing an additional 173,406 shares during the last quarter. Foresite Capital Management V LLC lifted its position in shares of Alumis by 3.5% in the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock worth $45,426,000 after buying an additional 194,459 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Alumis by 1,257.0% during the fourth quarter. BNP Paribas Financial Markets now owns 34,835 shares of the company’s stock valued at $274,000 after buying an additional 32,268 shares during the last quarter. Ally Bridge Group NY LLC grew its holdings in Alumis by 6.4% during the 4th quarter. Ally Bridge Group NY LLC now owns 445,259 shares of the company’s stock valued at $3,500,000 after buying an additional 26,843 shares in the last quarter. Finally, Foresite Capital Management VI LLC bought a new stake in Alumis in the 4th quarter worth approximately $33,033,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.